Patents by Inventor James Treanor

James Treanor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TAU AGGREGATION INHIBITORS
    Publication number: 20230137562
    Abstract: This invention relates to the field of tau aggregation inhibitors. More specifically, the invention relates to anti-amyloid therapeutics. More specifically, the invention provides pharmaceutical compositions and methods of treating aggregation associated conditions or diseases with certain peptides.
    Type: Application
    Filed: June 7, 2018
    Publication date: May 4, 2023
    Inventors: Shiho Tanaka, Ashley Wright, James Treanor, Marcin Apostol
  • Tau aggregation peptide inhibitors
    Patent number: 11453701
    Abstract: This invention relates to the field of tau aggregation inhibitors. More specifically, the invention relates to amyloid therapeutics. More specifically, the invention provides pharmaceutical compositions and methods of treating aggregation associated conditions or diseases with certain peptides.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: September 27, 2022
    Assignee: ADRX, INC.
    Inventors: Shiho Tanaka, Ashley Wright, James Treanor, Marcin Apostol, Matthew A. G. Graf
  • Peptide inhibitors of transcription factor aggregation
    Patent number: 11117930
    Abstract: This invention relates to materials, such as peptides, and methods to inhibit the aggregation transcription factors, for example p53 inhibitors, p63 inhibitors and p73 inhibitors. More specifically, the invention relates to cancer chemotherapeutics. More specifically, the invention provides pharmaceutical compositions and methods of treating cancer with certain peptides.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: September 14, 2021
    Assignee: ADRX, INC.
    Inventors: Shiho Tanaka, Ashley Wright, James Treanor, Marcin Apostol
  • TAU AGGREGATION PEPTIDE INHIBITORS
    Publication number: 20200216495
    Abstract: This invention relates to the field of tau aggregation inhibitors. More specifically, the invention relates to amyloid therapeutics. More specifically, the invention provides pharmaceutical compositions and methods of treating aggregation associated conditions or diseases with certain peptides.
    Type: Application
    Filed: August 20, 2018
    Publication date: July 9, 2020
    Inventors: Shiho Tanaka, Ashley Wrght, James Treanor, Marcin Apostol, Matthew A.G. Graf
  • PEPTIDE INHIBITORS OF TRANSCRIPTION FACTOR AGGREGATION
    Publication number: 20200062804
    Abstract: This invention relates to materials, such as peptides, and methods to inhibit the aggregation transcription factors, for example p53 inhibitors, p63 inhibitors and p73 inhibitors. More specifically, the invention relates to cancer chemotherapeutics. More specifically, the invention provides pharmaceutical compositions and methods of treating cancer with certain peptides.
    Type: Application
    Filed: February 23, 2018
    Publication date: February 27, 2020
    Inventors: Shiho Tanaka, Ashley Wright, James Treanor, Marcin Apostol
  • HUMAN ANTI-NGF NEUTRALIZING ANTIBODIES AS SELECTIVE NGF PATHWAY INHIBITORS
    Publication number: 20080033157
    Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
    Type: Application
    Filed: June 22, 2007
    Publication date: February 7, 2008
    Applicant: AMGEN INC.
    Inventors: Kenneth Wild, James Treanor, Haichun Huang, Heather Inoue, Tie Zhang, Frank Martin
  • Treatment of VR1-antagonist-induced increase in body temperature with an antipyretic agent
    Publication number: 20060281718
    Abstract: The present invention relates to a method of reducing a VR1-antagonist-induced increase in body temperature in a mammal in need thereof, comprising the step of administering an antipyretic agent to the mammal and the like.
    Type: Application
    Filed: May 12, 2006
    Publication date: December 14, 2006
    Inventors: Anthony Bannon, Klaus Beck, James Treanor
  • Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
    Publication number: 20050074821
    Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
    Type: Application
    Filed: July 15, 2004
    Publication date: April 7, 2005
    Inventors: Kenneth Wild, James Treanor, Haichun Huang, Heather Inoue, Tie Zhang, Frank Martin